Sushma Gorrela
Family Medicine · Spring, TXNPI 1063482321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 13 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$27
- Novartis$24
- Echosens North America, Inc.$22
- Lilly USA, LLC$21
- Bayer$21
- Medtronic$19
- plus $112 from 7 others
Across 119 payments — averaging $6512.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$452K
- Noven Pharmaceuticals, Inc.$185K
- Evofem Biosciences, Inc.$55K
- Kowa Research Institute, Inc.$47K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Pfizer$9K
- plus $13K from 2 others
What the payments were for
- Food & beverage$23194%
- Education$156%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 1 | $27 |
| Novartis | 1 | $24 |
| Echosens North America, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Bayer | 1 | $21 |
| Medtronic | 1 | $19 |
| GSK | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Novo Nordisk | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$246 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 34 | $575 |
| Losartan Potassium | 35 | $308 |
| Levothyroxine Sodium | 14 | $301 |
| Ezetimibe | 15 | $299 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $294 |
| Atorvastatin Calcium | 24 | $208 |
| Gabapentin | 15 | $206 |
| Metformin Hcl | 32 | $128 |
| Tamsulosin Hcl | 11 | $109 |
| Amlodipine Besylate | 18 | $95 |
| Furosemide | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Spring
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.